CN1594307A - Extraction separation for Nepal irid isoflavone from kudzu, process for preparing sulfonated compounds thereof , and their pharmaceutical uses - Google Patents
Extraction separation for Nepal irid isoflavone from kudzu, process for preparing sulfonated compounds thereof , and their pharmaceutical uses Download PDFInfo
- Publication number
- CN1594307A CN1594307A CN 200410026271 CN200410026271A CN1594307A CN 1594307 A CN1594307 A CN 1594307A CN 200410026271 CN200410026271 CN 200410026271 CN 200410026271 A CN200410026271 A CN 200410026271A CN 1594307 A CN1594307 A CN 1594307A
- Authority
- CN
- China
- Prior art keywords
- irisolidone
- formula
- isoflavone
- nepalese
- sodium sulfonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 68
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 16
- 238000000926 separation method Methods 0.000 title claims abstract description 14
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 235000010575 Pueraria lobata Nutrition 0.000 title claims abstract description 5
- 241000219781 Pueraria montana var. lobata Species 0.000 title claims abstract 4
- 150000001875 compounds Chemical class 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000000284 extract Substances 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 239000002904 solvent Substances 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 238000010438 heat treatment Methods 0.000 claims abstract description 11
- 238000010992 reflux Methods 0.000 claims abstract description 11
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 9
- 238000005903 acid hydrolysis reaction Methods 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000007787 solid Substances 0.000 claims description 39
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 38
- 239000000725 suspension Substances 0.000 claims description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 11
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 9
- 239000012043 crude product Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 claims description 8
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims 3
- 241001627160 Iris decora Species 0.000 claims 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims 1
- 241001126925 Lobata Species 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 238000011112 process operation Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 abstract description 69
- 229910052708 sodium Inorganic materials 0.000 abstract description 69
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract description 69
- 238000001953 recrystallisation Methods 0.000 abstract description 5
- SSWMJTJBIYKACI-UHFFFAOYSA-N 3-(4-oxochromen-3-yl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(C=2C(C3=CC=CC=C3OC=2)=O)=C1 SSWMJTJBIYKACI-UHFFFAOYSA-N 0.000 abstract 1
- 241001629703 Pueraria candollei var. mirifica Species 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- VOOFPOMXNLNEOF-UHFFFAOYSA-N Irisolidone Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=C(OC)C(O)=C2C1=O VOOFPOMXNLNEOF-UHFFFAOYSA-N 0.000 description 214
- MZERYTHMEZCPQG-UHFFFAOYSA-N junipegenin-B Natural products C1=C(OC)C(OC)=CC=C1C1=COC2=CC(O)=C(OC)C(O)=C2C1=O MZERYTHMEZCPQG-UHFFFAOYSA-N 0.000 description 107
- 241000628997 Flos Species 0.000 description 34
- 244000209700 shan ge teng Species 0.000 description 34
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- 238000001556 precipitation Methods 0.000 description 19
- 239000007788 liquid Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 238000004821 distillation Methods 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 11
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 239000000376 reactant Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- QTVAYNGFFDZGDR-CIJVEFAYSA-N 5-hydroxy-6-methoxy-3-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)O3)O)=C(OC)C(O)=C2C1=O QTVAYNGFFDZGDR-CIJVEFAYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- MYJXWCIZOOKQLK-UHFFFAOYSA-N kakkalide Natural products COc1cc2C(=O)C(=COc2cc1OC3OC(COC4OCC(O)C(O)C4O)C(O)C(O)C3O)c5ccc(O)cc5 MYJXWCIZOOKQLK-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 229960000715 nimodipine Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000219780 Pueraria Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- -1 Irisolidone glucoside Chemical class 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000012451 post-reaction mixture Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种从野葛花中提取分离尼泊尔鸢尾异黄酮的方法和尼泊尔鸢尾异黄酮－3′－磺酸钠制备方法。提取分离工艺为：野葛花粉末，加溶剂加热回流或超声波提取，提取物经正丁醇萃取、稀酸水解、过滤、重结晶和烘干得尼泊尔鸢尾异黄酮。制备工艺为：在溶剂中加入尼泊尔鸢尾异黄酮，再加入磺化剂进行反应，用常规分离方法纯化得尼泊尔鸢尾异黄酮－3′－磺酸钠。还提供了－种治疗心、脑血管疾病的药物和组合物，其中有治疗有效量的尼泊尔鸢尾异黄酮或尼泊尔鸢尾异黄酮－3′－磺酸钠和药学上可接受的载体；以及尼泊尔鸢尾异黄酮和尼泊尔鸢尾异黄酮－3′－磺酸钠在制备治疗心、脑血管疾病的药物中的应用。The invention provides a method for extracting and isoflavone from kudzu flower and a preparation method of iris isoflavone-3'-sodium sulfonate. The extraction and separation process is as follows: Pueraria mirifica powder, adding a solvent and heating to reflux or ultrasonic extraction, and the extract is extracted with n-butanol, dilute acid hydrolysis, filtration, recrystallization and drying to obtain the isoflavones of Nepalese iris. The preparation process is as follows: add Nepalese isoflavone to the solvent, then add sulfonating agent for reaction, and purify by conventional separation method to obtain Nepalese isoflavone-3'-sodium sulfonate. Also provided is a medicine and composition for treating cardiovascular and cerebrovascular diseases, wherein there is a therapeutically effective amount of Nepalese isoflavone or Nepalese isoflavone-3'-sodium sulfonate and a pharmaceutically acceptable carrier; and Nepalese isoflavone Application of isoflavone and Nepalese iris isoflavone-3'-sulfonate in the preparation of medicine for treating cardiovascular and cerebrovascular diseases.
Description
Technical field
The invention belongs to the heterogeneous ring compound technical field, be specifically related to heterocycle not hydrogenant contain six-membered ring, Sauerstoffatom is arranged as ring hetero atom is only arranged, with other ring condensed heterocycle compounds.
Background technology
Radix Puerariae (Pueraria lobata (wild) Ohwi) is a pulse family Pueraria lobota platymiscium, and china natural resources is extensive, is mainly used in the Kaiyang expelling pathogenic factors from muscles and skin, promoting eruption antidiarrheal, and anti-tired pain relieving, it is cold to cure the wound, warm headache Xiang Qiang, hypertension, stenocardia etc.The Chinese medicine FI puerariae is the dried flower flower bud of leguminous plants Pueraria lobota, has another name called the Pueraria lobota barriness, and pharmacopeia puts down in writing that its property is sweet, and cold is used for relieving acute alcoholism and recuperating the spleen, the wine that cures the wound heating, and polydipsia, anorexia, discharging fresh blood stool etc. are spitted blood in the contrary acid regurgitation of vomitting.FI puerariae is the conventional medicament of China, is used to alleviate symptoms such as vomiting after drinking for a long time, and its main effective constituent is isoflavone compounds.Irisolidone (Irisolidone, 5,7-dihydroxyl-4 ', 6-dimethoxy isoflavones) and be the aglycon of the main active ingredient Kakkalide (Kakkalide) of Chinese medicine Flos Pueraria omeiensis, Kakkalide is poisoned to alleviation of alcohol and the protection liver injury has better curative effect.The bibliographical information Irisolidone has intensive and suppresses the Hp effect, and the MIC of bacteriostatic action is only than the high order of magnitude of tsiklomitsin.Irisolidone is a kind of good newtype drug precursor, has the potential using value.Simultaneously, isoflavone is because water-soluble and fat-soluble all lower, when medicinal, can only make medicinal preparation for oral administration and can not make injection, because theirs is water-soluble very low, have influence on drug utilization degree and effective time, in order to reach therapeutic purpose, during clinical use, patient's dose is big, take medicine and just can observe result of treatment after 1～2 week, thus the invention provides a kind of water-soluble isoflavone compounds Irisolidone-3 '-sodium sulfonate and preparation method thereof.Extraction and separation method about Irisolidone in the Flos Pueraria omeiensis, only adopt preparative chromatography to separate preparation at present, the invention provides a kind ofly with Flos Pueraria omeiensis extract n-butanol extraction, extract directly prepares the method for Irisolidone through dilute acid hydrolysis by recrystallization.
Summary of the invention
The object of the present invention is to provide a kind of from Flos Pueraria omeiensis the method for extraction separation Irisolidone.
Another object of the present invention is to overcome the medicinal shortcoming of Irisolidone, and a kind of water-soluble high new compound with pharmaceutical use is provided: Irisolidone-3 '-sodium sulfonate.
Further purpose of the present invention be to provide a kind of prepare Irisolidone-3 '-method of sodium sulfonate.
The 4th purpose of the present invention is to provide a kind of medicine and composition for the treatment of the heart, cerebrovascular disease.
The 5th purpose of the present invention is to provide a kind of above-claimed cpd and the application of composition in the medicine of the preparation treatment heart, cerebrovascular disease.
Irisolidone of the present invention and Irisolidone-3 '-chemical name of sodium sulfonate is respectively 5,7-dihydroxyl-6,4 '--dimethoxy isoflavones and 5,7-dihydroxyl-6,4 '--dimethoxy isoflavones-3 '-sodium sulfonate, their chemical structure is used following formula (I) and formula (II) expression respectively:
Formula (I) formula (II)
The operational path of extraction separation Irisolidone may further comprise the steps from Flos Pueraria omeiensis:
(1) exsiccant Flos Pueraria omeiensis, the solvent reflux or the ultrasonic extraction of 4～6 times of amounts of adding, the heating and refluxing extraction time is each 2 hours, the ultrasonic extraction time is each 30 minutes, filters, time extracting solution and the filter residue of extraction of winning.The solvent that filter residue adds 4～6 times of amounts again extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.
(2) add suitable quantity of water in the paste of extracting for (1) and stir into suspension, the proportion that makes suspension is between 1.15～1.30, use the n-butanol extraction 3～5 times of 0.5～0.8 times of volume of suspension respectively, the extraction liquid of 3～5 propyl carbinols is evaporated to dried solids.
(3) give in the solids of (3) n-butanol extraction, 2～5% hydrochloric acid that adding solids weight is 3 times or the hydrolysis of sulfuric acid reflux 1 hour have precipitation to occur, this precipitation of decompress filter also washes with water to nearly neutrality, the oven dry, use the dehydrated alcohol recrystallization, suction filtration, dry compound formula (I).
Among the preparation method of the present invention's extraction separation Irisolidone from Flos Pueraria omeiensis, the solvent of extraction is water or methyl alcohol or ethanol or water and methanol mixture or water and alcoholic acid mixture.In water and methanol mixture or water and the alcoholic acid mixture volume of water and methyl alcohol or alcoholic acid volume ratio be arbitrarily than.
Among the preparation method of the present invention's extraction separation Irisolidone from Flos Pueraria omeiensis, the exsiccant Flos Pueraria omeiensis, the mode that adds solvent extraction both can be a reflux, also can be ultrasonic extraction.Ultrasonic wave can cause the cavatition of solvent, and cavatition produces partial High Temperature High Pressure, can enhancing substance dissolving power in solvent.The macroscopical turbulence that acoustic streaming that ultrasonic cavitation produces and shockwave can cause system and the high velocity impact of solid particulate make the attenuation of mass transfer frictional belt, and rate of mass transfer increases.Compare with conventional solvent extraction, the supersound extraction time is short, productive rate is high, mild condition; Special roles such as hyperacoustic pulverizing, stirring can be broken the cell walls of vegetable drug, so that solvent is penetrated in the crude drug cell as early as possible, stripping is chemical ingredients wherein.The ultrasonic extraction time of the present invention is only used 30 minutes at every turn, saves extraction time than heating reflux method.
The content of Irisolidone is not high in Flos Pueraria omeiensis, and the glycosides of Irisolidone---the content of Kakkalide is than higher, the Flos Pueraria omeiensis extract is added suitable quantity of water stir into the suspension n-butanol extraction, can change Kakkalide and Irisolidone over to propyl carbinol mutually, with separating of realization and water-soluble impurity.Again with the n-butyl alcohol extract of Flos Pueraria omeiensis with 2～5% hydrochloric acid or sulphuric acid hydrolysis, Kakkalide is hydrolyzed into Irisolidone, help improving the productive rate of Irisolidone like this.
The preparation method of the present invention's extraction separation Irisolidone from Flos Pueraria omeiensis has advantage with short production cycle, that product yield is high, equipment is simple and product cost is low.
Adopt chemical reaction prepare Irisolidone of the present invention-3 '-method of sodium sulfonate is as follows:
(1) in reactor, adds solvent and Irisolidone, make Irisolidone be dissolved in the solvent fully under stirring, add sulphonating agent again, make Irisolidone and sulphonating agent carry out chemical reaction, the mol ratio of used Irisolidone and sulphonating agent is 1: 1～1: 10, making the temperature of reaction solution with register is 20～100 ℃, reacted 20 minutes～10 hours, Irisolidone-3 '-mixture of sulfonic acid and unreacted reactant.
(2) (1) post reaction mixture is cooled to room temperature, the sodium chloride solution that adds 1～5 times of amount 10～20% of reactant cumulative volume, fully stir, leave standstill and generate precipitation, use conventional separation method, (II) separates with formula, obtains crude product, 1～5 times of amount 10～20% sodium chloride solution that adds the crude product amount again make its purifying, obtain the pure product of formula (II) compound.
Formula (II)
Irisolidone of the present invention-3 '-preparation method of sodium sulfonate in, the used sulphonating agent of chemical reaction can be the vitriol oil or chlorsulfonic acid or oleum or sulphur trioxide.
Irisolidone of the present invention-3 '-preparation method of sodium sulfonate in, the solvent that reacts used is 70～98% sulfuric acid.
Irisolidone of the present invention-3 '-preparation method of sodium sulfonate in, the preferred temperature of sulfonation reaction is 40～80 ℃, the preferred time of chemical reaction is 2～8 hours.
Irisolidone of the present invention-3 '-preparation method of sodium sulfonate in, the optimum temps of chemical reaction is 60 ℃, the Best Times of chemical reaction is 4 hours.
Pharmaceutical composition of the present invention contains the above-claimed cpd formula (I) or the compound formula (II) for the treatment of significant quantity and is active ingredient, and contains one or more pharmaceutically acceptable carriers.
Compound of the present invention and pharmaceutical composition can be used for preparing the application in the treatment heart, the cerebrovascular disease medicament.
Effective constituent Irisolidone-3 of the present invention '-sodium sulfonate or the Irisolidone preparation treatment heart, cerebrovascular disease medicament use with the form of conventional medicinal preparations; Described conventional medicinal preparations contain Irisolidone-3 as activeconstituents '-sodium sulfonate or Irisolidone, this activeconstituents in preparation with pharmaceutically acceptable carrier as being suitable in the stomach and intestine and the solid or the liquid excipient of the organic or inorganic of parenteral admin mix.Irisolidone-3 '-the sodium sulfonate medicinal preparations can be solid form such as tablet, granule, pulvis, capsule; Also can be liquid form such as injection, suspension agent, syrup and emulsion etc.; The Irisolidone medicinal preparations can be solid form such as tablet, granule, pulvis, capsule.
Can contain auxiliary substance, stablizer in the above-mentioned preparation, wetting agent and other additive commonly used are as lactose, citric acid, tartrate, stearic acid, Magnesium Stearate, terra alba, sucrose, W-Gum, talcum powder, gelatin, agar, pectin, peanut oil, sweet oil, theobroma oil, ethylene glycol, glucose, vovocan, Xylotox and xitix etc.
Above-mentioned preparation can be made according to the preparation technology of various preparation routines.
It is 0.1～99.5% activeconstituents that pharmaceutical composition of the present invention preferably contains weight ratio, most preferably contains weight ratio and be 0.5～95% activeconstituents.
Activeconstituents Irisolidone-3 of the present invention '-sodium sulfonate makes the oral pharmaceutical of various formulations, Irisolidone is made the various formulation oral pharmaceutical except that liquid preparation, become human oral, Irisolidone in the medicine-3 '-content of sodium sulfonate or Irisolidone should be 150mg every day, three times on the one, Irisolidone-3 in each medicine '-content of sodium sulfonate or Irisolidone is 50mg, 14 days is a course of treatment, treats 2～3 courses of treatment.Adult's intramuscular injection, Irisolidone in the medicine-3 '-sodium sulfonate content should be 80mg every day, and twice, 14 day on the one is a course of treatment, treats 2 courses of treatment; Intravenous drip, adult's consumption, Irisolidone in the medicine-3 '-content of sodium sulfonate should be 80mg every day, and once-a-day, 14 days is a course of treatment, treats 2 courses of treatment.Oral pharmaceutical or injectable drug, children is taken the circumstances into consideration decrement.
The contriver with activeconstituents Irisolidone-3 of the present invention '-sodium sulfonate and Irisolidone consignment test unit carried out the test of pesticide effectiveness, test-results show activeconstituents Irisolidone-3 of the present invention '-sodium sulfonate and Irisolidone have oxygen lack resistant function preferably to small white mouse.If with Irisolidone-3 '-sodium sulfonate and Irisolidone be used for clinical trial, expection will have better therapeutic effect.
The present invention adopt the electrophilic substitution sulfonation reaction prepare Irisolidone-3 '-sodium sulfonate, advantage such as it is easy to have technology, and used equipment is simple, the yield height of product and production cost are low.
Description of drawings
Fig. 1 is the infrared spectrogram of Irisolidone of the present invention.
Fig. 2 is the hydrogen nuclear magnetic resonance spectrogram of Irisolidone of the present invention.
Fig. 3 is an Irisolidone of the present invention
13C mr spectrogram.
Fig. 4 be Irisolidone of the present invention-3 '-infrared spectrogram of sodium sulfonate.
Fig. 5 be Irisolidone of the present invention-3 '-the hydrogen nuclear magnetic resonance spectrogram of sodium sulfonate.
In Fig. 1 and Fig. 4, X-coordinate is a wave number, and ordinate zou is a specific absorption.In Fig. 2, Fig. 3 and Fig. 5, X-coordinate is chemical shift, and unit is ppm, and ordinate zou is a peak heights.
Embodiment
The present invention is described in more detail below in conjunction with drawings and Examples, but the invention is not restricted to these embodiment.
One, Irisolidone prepares embodiment
Get the Flos Pueraria omeiensis powder and add reactor, add 5 times of water gagings again, reflux 2 hours is filtered, time extracting solution and the filter residue of extraction of winning.The water that filter residue adds 5 times of amounts of Flos Pueraria omeiensis powder again extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.15, uses the n-butanol extraction 4 times of 0.6 times of volume of suspension respectively, and the extraction liquid of 4 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 5% hydrochloric acid reflux hydrolysis that adding solids weight is 3 times 1 hour, there is precipitation to occur, this precipitation of decompress filter also washes with water to nearly neutrality, and dehydrated alcohol recrystallization 3 times are used in oven dry, suction filtration, dry the pure product of formula (I), light yellow needle-like crystal, fusing point are 237-238 ℃, and extraction yield is 0.8%.
Referring to Fig. 1, the Irisolidone molecular structure of present embodiment is as follows through the infrared spectrometer test result:
IR(KBr)ν：3449.6，2956.4，1460.5，1659.3，1619.6，1575.8，1513.8，1065.8cm
-1.
Referring to Fig. 2, the H in the Irisolidone molecular structural formula of present embodiment is as follows with the nuclear magnetic resonance analyser test result:
1H?NMR(DMSO-d
6，300MHz)：8.34(1H，s，H-C
2)，6.50(1H，s，H-C
8)，7.42(2H，d，J＝8.8Hz，H-C
2’，H-C
6’)，6.92(2H，d，J＝8.8Hz，H-C
3’，H-C
5’)，3.78(1H，s，C
6-OCH
3)，3.75(3H，s，C
4-OCH
3)，12.96(1H，s，5-OH)，10.8(1H，s，7-OH)。
Referring to Fig. 3, the 13C in the Irisolidone molecular structural formula of present embodiment is as follows with the nuclear magnetic resonance analyser test result:
1H?NMR(DMSO-d
6)：154.8(C-2)，122.0(C-3)，181.0(C-4)，153.0(C-5)，131.8(C-6)，157.8(C-7)，94.6(C-8)，105.4(C-8a)，153.6(C-4a)，123.4(C-1′)，130.6(C-2′，C-6′)，114.4(C-3′，C-5′)，159.8(C-4′)，60.4(6′-OCH
3)，55.6(4′-OCH
3)。
Get the FI puerariae powder and add reactor, add 6 times of water gagings again, ultrasonic extraction 30 minutes is filtered, time extracting solution and the filter residue of extraction of winning.The water that filter residue adds 5 times of amounts of Flos Pueraria omeiensis powder again extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.18, uses the n-butanol extraction 5 times of 0.5 times of volume of suspension respectively, and the extraction liquid of 5 propyl carbinols is evaporated to dried solids.N-butanol extraction gets in the solids, and the 4% hydrochloric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.Present embodiment extracts Irisolidone from Flos Pueraria omeiensis extraction yield is 0.9%.
Get the FI puerariae powder and add reactor, add 6 times of amount ethanol again, ultrasonic extraction 30 minutes is filtered, time extracting solution and the filter residue of extraction of winning.The ethanol that filter residue adds 5 times of amounts of Flos Pueraria omeiensis powder again extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.22, uses the n-butanol extraction 3 times of 0.8 times of volume of suspension respectively, and the extraction liquid of 3 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 2% sulfuric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.Present embodiment extracts Irisolidone from Flos Pueraria omeiensis extraction yield is 1.0%.
Get the FI puerariae powder and add reactor, add 4 times of amount methyl alcohol again, ultrasonic extraction 30 minutes is filtered, time extracting solution and the filter residue of extraction of winning.The ethanol that filter residue adds 4 times of amounts of Flos Pueraria omeiensis powder again extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.15, uses the n-butanol extraction 4 times of 0.7 times of volume of suspension respectively, and the extraction liquid of 4 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 2% sulfuric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.Present embodiment extracts Irisolidone from Flos Pueraria omeiensis extraction yield is 1.1%.
Get the FI puerariae powder and add reactor, add 5 times of amount ethanol again, heating and refluxing extraction 2 hours is filtered, time extracting solution and the filter residue of extraction of winning.The ethanol that filter residue adds 5 times of amounts of Flos Pueraria omeiensis powder again extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.30, uses the n-butanol extraction 5 times of 0.6 times of volume of suspension respectively, and the extraction liquid of 5 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 5% hydrochloric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.Present embodiment extracts Irisolidone from Flos Pueraria omeiensis extraction yield is 0.9%.
Embodiment 6
Get the FI puerariae powder and add reactor, add 6 times of amount methyl alcohol again, heating and refluxing extraction 2 hours is filtered, time extracting solution and the filter residue of extraction of winning.The ethanol that filter residue adds 5 times of amounts of Flos Pueraria omeiensis powder again extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.20, uses the n-butanol extraction 4 times of 0.5 times of volume of suspension respectively, and the extraction liquid of 4 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 2% sulfuric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.Present embodiment extracts Irisolidone from Flos Pueraria omeiensis extraction yield is 1.0%.
Get the FI puerariae powder and add reactor, add 5 times of water gagings and ethanol volume ratio again and be 1: 1 mixture, heating and refluxing extraction 2 hours is filtered, the extracting solution and the filter residue of winning and time extracting.Water and 1: 1 mixture of ethanol that filter residue adds 5 times of amounts of Flos Pueraria omeiensis powder again extract twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.28, uses the n-butanol extraction 5 times of 0.7 times of volume of suspension respectively, and the extraction liquid of 5 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 2% hydrochloric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.Present embodiment extracts Irisolidone from Flos Pueraria omeiensis extraction yield is 0.9%.
Embodiment 8
Get the FI puerariae powder and add reactor, add 6 times of water gagings and methyl alcohol volume ratio again and be 1: 1 mixture, ultrasonic extraction 30 minutes is filtered, the extracting solution and the filter residue of winning and time extracting.Filter residue adds 5 times of water gagings of Flos Pueraria omeiensis powder again and 1: 1 mixture of methyl alcohol extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.25, uses the n-butanol extraction 3 times of 0.5 times of volume of suspension respectively, and the extraction liquid of 3 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 4% sulfuric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.Present embodiment extracts Irisolidone from Flos Pueraria omeiensis extraction yield is 1.0%.
Embodiment 9
Get the FI puerariae powder and add reactor, add 5 times of water gagings and ethanol volume ratio again and be 9: 1 mixture, ultrasonic extraction 30 minutes is filtered, the extracting solution and the filter residue of winning and time extracting.Water and 9: 1 mixture of ethanol that filter residue adds 5 times of amounts of Flos Pueraria omeiensis powder again extract twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.20, uses the n-butanol extraction 3 times of 0.7 times of volume of suspension respectively, and the extraction liquid of 3 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 4% hydrochloric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.The yield of Irisolidone is 0.9% in the present embodiment Flos Pueraria omeiensis.
Get the FI puerariae powder and add reactor, add 6 times of water gagings and methyl alcohol volume ratio again and be 1: 9 mixture, heating and refluxing extraction 2 hours is filtered, the extracting solution and the filter residue of winning and time extracting.Filter residue adds 4 times of water gagings of Flos Pueraria omeiensis powder again and 1: 9 mixture of methyl alcohol extracts twice according to the method for extracting the above-mentioned first time again.The extracting solution that extracts for three times merges, and underpressure distillation is to paste.Add suitable quantity of water in the paste and stir into suspension, the proportion that makes suspension is 1.20, uses the n-butanol extraction 4 times of 0.5 times of volume of suspension respectively, and the extraction liquid of 4 propyl carbinols is evaporated to dried solids.In the solids of n-butanol extraction, the 3% sulfuric acid reflux hydrolysis that adding solids weight is 3 times 1 hour has precipitation to occur.Other technological process is identical with embodiment 1.The yield of Irisolidone is 1.0% in the present embodiment Flos Pueraria omeiensis.
Two, Irisolidone-3 '-sodium sulfonate prepares embodiment
Embodiment 11
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 80% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, add the sulphonating agent vitriol oil again, the mol ratio of the Irisolidone and the vitriol oil is 1: 5, after the stirrer stirring, making the temperature of reaction solution with register is 60 ℃, reacts 1 hour, obtain Irisolidone-3 '-mixture of sulfonic acid and unreacting material, be cooled to room temperature, 10% sodium chloride aqueous solution that adds 5 times of reactant cumulative volumes fully stirs, and leaves standstill and separates out precipitation, filter, obtain Irisolidone-3 '-the sodium sulfonate crude product; With recrystallization method Irisolidone-3 '-10% sodium chloride aqueous solution that adds 5 times of amounts in the sodium sulfonate crude product carries out purifying, obtain Irisolidone-3 '-sodium sulfonate elaboration (productive rate 88%).
Adopt the Irisolidone-3 of this examples preparation '-sodium sulfonate, after tested, its physicochemical property is as follows:
Light yellow needle-like crystal, fusing point are 318 ℃ (decomposition); Solubleness in water is 7.4%, and is soluble in water; Thin layer shows light basket look fluorescence.
Referring to Fig. 4, the Irisolidone of present embodiment-3 '-the infrared spectrometer test result of sodium sulfonate is as follows:
IR(KBr)ν：3452.0，3069.7，2946.3，2843.9，1654.2，1625.6，1579.5，1496.4，1464.3，1367.4，1337.6，1262.1，1189.5，1156.4，1097.3，1071.5，1033.1，1001.7cm
-1。
Referring to Fig. 5, the Irisolidone of present embodiment-3 '-H of sodium sulfonate is as follows with the nuclear magnetic resonance analyser test result:
1H?NMR(DMSO-d
6，300MHz)：8.37(s，1H，H-C
2)，7.90(d，J＝2.2Hz，1H，H-C
2’)，7.49(dd，J＝2.2Hz，J＝8.6Hz，1H，H-C
6’)，7.06(d，J＝8.6Hz，1H，H-C
5’)，6.55(s，1H，H-C
8)，3.81(s，3H，C
6-OCH
3)，3.76(s，3H，C
4’-OCH
3)，13.03(s，1H，C
5-OH)，10.87(s，1H，C
7-OH)。
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 70% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, add the sulphonating agent vitriol oil again, the mol ratio of the Irisolidone and the vitriol oil is 1: 8, after the stirrer stirring, making the temperature of reaction solution with register is 100 ℃, react 20 clocks, obtain Irisolidone-3 '-mixture of sulfonic acid and unreacted reactant, be cooled to room temperature, add 5 times of volume 10% sodium chloride aqueous solutions, place, obtain Irisolidone-3 '-sodium sulfonate precipitation, separate subsequently Irisolidone-3 '-sodium sulfonate, and make its purifying, separation and purifying are raw materials used to be 20% sodium chloride aqueous solution of 1 times of reactant cumulative volume, and other technological process is identical with embodiment 1.
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 98% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, add the sulphonating agent vitriol oil again, the mol ratio of the Irisolidone and the vitriol oil is 1: 3, after the stirrer stirring, making the temperature of reaction solution with register is 20 ℃, reacted 10 hours, obtain Irisolidone-3 '-mixture of sulfonic acid and unreacted reactant, add 5 times of volume 10% sodium chloride aqueous solutions, place, obtain Irisolidone-3 '-the sodium sulfonate precipitation, separate subsequently Irisolidone-3 '-sodium sulfonate, and make its purifying, separate raw materials used and proportioning is identical with embodiment 1 with purifying.
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 90% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, add the sulphonating agent vitriol oil again, Irisolidone unit is 1: 1 with the mol ratio of the vitriol oil, after the stirrer stirring, making the temperature of reaction solution with register is 80 ℃, reacted 50 minutes, obtain Irisolidone-3 '-mixture of sulfonic acid and unreacted reactant, be cooled to room temperature, add 5 times of volume 10% sodium chloride aqueous solutions, place, obtain Irisolidone-3 '-the sodium sulfonate precipitation, separate subsequently Irisolidone-3 '-sodium sulfonate and make its purifying, separate raw materials used and proportioning is identical with embodiment 1 with purifying.
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 85% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, add the sulphonating agent vitriol oil again, Irisolidone unit is 1: 6 with the mol ratio of the vitriol oil, after the stirrer stirring, making the temperature of reaction solution with register is 20 ℃, reacted 10 hours, obtain Irisolidone-3 '-mixture of sulfonic acid and unreacted reactant, be cooled to room temperature, add 5 times of volume 10% sodium chloride aqueous solutions, place, Irisolidone-3 '-the sodium sulfonate precipitation, separate subsequently Irisolidone-3 '-sodium sulfonate and make its purifying, separate raw materials used and proportioning is identical with embodiment 1 with purifying.
Embodiment 16
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 70% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, add the sulphonating agent oleum again, Irisolidone and oleum mol ratio are 1: 3, after the stirrer stirring, be warming up to 50～55 ℃, reacted 1 hour, obtain Irisolidone-3 '-mixture of sulfonic acid and unreacted reactant, be cooled to room temperature, add 10% sodium chloride aqueous solution, obtain Irisolidone-3 '-the sodium sulfonate crude product, and make its purifying.Separate raw materials used and proportioning is identical with embodiment 1 with operation with purifying.
Embodiment 17
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 85% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, add the sulphonating agent chlorsulfonic acid again, Irisolidone and chlorsulfonic acid mol ratio are 1: 2, after the stirrer stirring, be warming up to 45～50 ℃, reacted 2 hours, reaction-ure mixture is cooled to room temperature, add 10% sodium chloride aqueous solution heating back and cooling, obtain Irisolidone-3 '-the sodium sulfonate crude product.Separate raw materials used and proportioning is identical with embodiment 1 with operation with purifying.
Embodiment 18
In the present embodiment, earlier Irisolidone is added in the reactor, also add solvent 80% sulfuric acid gradually with the stirrer stirring up to Irisolidone is fully dissolved, feed the sulphonating agent sulphur trioxide again, Irisolidone and sulphur trioxide mol ratio are 1: 2, after the stirrer stirring, be warming up to 45～50 ℃, reacted 2 hours, obtain Irisolidone-3 '-mixture of sulfonic acid and unreacted reactant, be cooled to room temperature, add 10% sodium chloride aqueous solution heating back and cooling, obtain Irisolidone-3 '-the sodium sulfonate crude product.Separate raw materials used and proportioning is identical with embodiment 1 with operation with purifying.
Three, Irisolidone-3 '-sodium sulfonate and Irisolidone example of formulations
With preparation Irisolidone of the present invention-3 '-sodium sulfonate or 1000 in Irisolidone tablet are that used raw material of example and ratio of adjuvant are as follows:
Irisolidone-3 '-sodium sulfonate or
Irisolidone 50g
Starch 250g
Starch slurry (10%) 85g
Magnesium Stearate 15g
Adopt the preparation technology of conventional tablet to make, every heavy 0.4g, every Irisolidone-3 '-content of sodium sulfonate or Irisolidone is 50mg.Usage: be grown up three times on the one, each 1 oral, children take the circumstances into consideration decrement.
With preparation Irisolidone of the present invention-3 '-sodium sulfonate or Irisolidone powder are that used raw material of example and ratio of adjuvant are as follows for 1000 bags:
Irisolidone-3 '-sodium sulfonate or
Irisolidone 40g
Lactose 2800g
Starch slurry (10%) 60g
Adopt the preparation technology of conventional powder to make, every bag heavy 3g, every Irisolidone-3 '-content of sodium sulfonate or Irisolidone is 40mg.Usage: be grown up three times on the one, each 1 sack clothes, children take the circumstances into consideration decrement.
Embodiment 21
With the preparation Irisolidone of the present invention-3 '-sodium sulfonate 1000ml injection is an example, used raw material and ratio of adjuvant are as follows:
Irisolidone-3 '-sodium sulfonate 50g
Water for injection adds to 1000ml
Adopt the preparation technology of conventional method injection to make, every bottle of 2ml, contain Irisolidone-3 '-sodium sulfonate 100mg.Usage: intramuscular injection, one day twice, each 1, intravenous drip, once-a-day, each 2.
The contriver with effective constituent Irisolidone-3 of the present invention '-sodium sulfonate and Irisolidone consignment test unit carried out the test of pesticide effectiveness, exemplify following experiment content and test-results thereof, prove with the pharmacological agent heart of the present invention's preparation, the validity of cerebrovascular disease.
The test of pesticide effectiveness
The ICR mouse is provided by the Traditional Chinese Medicine Research Institute, Shanxi Province Experimental Animal Center, body weight 20～22g, and in mouse 6-7 in age week, the animal conformity certification moves word 08-24 number for the doctor.
1. anti-hypoxia, ischemia resisting effect
(1) animal grouping and handle laboratory animal be divided at random blank group, positive drug control group, the heavy dose of group of Irisolidone and small dose group, Irisolidone-3 '-totally six groups of the heavy dose of group of sodium sulfonate and small dose group, every group of 12 mouse, blank group is irritated stomach and give equal-volume solvent (Xylo-Mucine suspension liquid) every day, and the heavy dose of and low dose of Irisolidone is respectively 150mgkg
-1D
-1, and 50mgkg
-1, Irisolidone-3 '-the heavy dose of and low dose of sodium sulfonate is respectively 150mgkg
-1D
-1, and 50mgkg
-1D
-1, gastric infusion, 7 days aftertreatment animals of successive administration.
(2) testing method of each index
The acute brain hypoxia test: by (1) described method grouping, with the positive medicine of nimodipine, dosage is 120mgkg
-1D
-1, behind the last administration 1h, breaking end rapidly from the mouse ear rear portion, the record mouse once breathes the time to the end from the broken end beginning.
The chemical hypoxia test: by (1) described method grouping, with the positive medicine of nimodipine, dosage is 120mgkg-1d-1, and behind the last administration 1h, each organizes equal abdominal injection Sodium Nitrite 200mgkg
-1, opening entry mouse survival time immediately.
Cardiac muscle specificity hypoxia test: on (1) described method packet by packet basis, increase model control group again.Blank group and model control group all give the equal-volume solvent, and with the positive medicine of propranolol hydrochloride, dosage is 120mgkg
-1D
-1, behind the last administration 40min, except that the blank group, all the other are respectively organized equal abdominal injection and give 10mgkg
-1Racemic isoproterenol, give Racemic isoproterenol 15min after, it is flat to place volume to be that 200mL is equipped with the wide-mouth of 10g sodica calx each group mouse, sealing, record mouse diing time.
(3) experimental result
Irisolidone-3 '-sodium sulfonate and Irisolidone to the effect of acute cerebral ischemia mouse, to the effect of chemical anoxic mouse and to the effect of myocardium specificity anoxic mouse see Table 1 respectively, table 2 and table 3.
Table 1 Irisolidone and sodium sulfonate thereof to the effect of acute cerebral ischemia mouse (x ± s, n=12)
Group dosage (mgkg
-1D
-1) survival time (s)
Blank group-20.28 ± 1.96
Nimodipine control group 120 23.45 ± 1.89
*
The heavy dose of group 150 22.37 ± 1.68 of Irisolidone
*
Irisolidone small dose group 50 23.49 ± 2.42
*
Irisolidone-3 '-the heavy dose of group 150 22.67 ± 2.50 of sodium sulfonate
*
Irisolidone-3 '-sodium sulfonate small dose group 50 22.25 ± 2.19
*
Annotate:
*Expression is compared with model control group
*P＜0.05,
*P＜0.01, down together
Table 2 Irisolidone and sodium sulfonate thereof to the effect of chemical anoxic mouse (x ± s, n=12)
Group dosage (mgkg
-1D
-1) survival time (min)
Blank group-11.93 ± 1.31
Nimodipine control group 120 14.95 ± 2.45
*
The heavy dose of group 150 14.74 ± 3.72 of Irisolidone
*
Irisolidone small dose group 50 13.43 ± 2.51
Irisolidone-3 '-the heavy dose of group 150 13.45 ± 1.70 of sodium sulfonate
*
Irisolidone-3 '-sodium sulfonate small dose group 50 13.36 ± 2.24
Table 3 Irisolidone and sodium sulfonate thereof to the effect of myocardium specificity anoxic mouse (x ± s, n=12)
Group dosage (mgkg
-1D
-1) survival time (min)
Blank group-40.83 ± 6.98
Model control group-21.93 ± 2.90
*
Nimodipine control group 120 27.76 ± 4.83
*
The heavy dose of group 150 28.03 ± 3.70 of Irisolidone
*
Irisolidone small dose group 50 29.12 ± 2.65
*
Irisolidone-3 '-the heavy dose of group 150 28.05 ± 6.02 of sodium sulfonate
*
Irisolidone-3 '-sodium sulfonate small dose group 50 25.32 ± 3.51
*
2. conclusion
Behind the mouse broken end, because cerebral blood supply stops, original blood and nutritive substance still can make brain function keep blink in the brain at short notice, and the mouse demonstration clocklike dehisces to breathe, and all medicines that the brain oxygen-consumption is reduced all can prolong mouse and breathe the time; After Sodium Nitrite enters in the body, can with the oxyphorase combination, make it lose the ability of carrying oxygen, thereby the histanoxia of causing causes animal dead; After giving Racemic isoproterenol, heart rate is accelerated, and myocardial contraction strengthens, and myocardial consumption of oxygen rises, and when anoxic, the myocardial cell comes to harm at first, thereby causes animal dead.Have to reduce and organize oxygen-consumption, vasodilation promotes blood flow rate, improves the utilization ratio of oxygen in the tissue, coronary artery dilator, and the medicine that reduces functions such as myocardial consumption of oxygen all can prolong the animal caused by anoxia dead time.This test as can be seen, Irisolidone-3 '-sodium sulfonate, Irisolidone all can prolong the anoxic death time of animal effectively, have significantly oxygen lack resistant function.In addition, after Irisolidone glucoside unit is sulfonated, improved significantly that it is water-soluble, its anti-anoxia ability and the first basically identical of Irisolidone glucoside.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410026271 CN1594307A (en) | 2004-06-25 | 2004-06-25 | Extraction separation for Nepal irid isoflavone from kudzu, process for preparing sulfonated compounds thereof , and their pharmaceutical uses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410026271 CN1594307A (en) | 2004-06-25 | 2004-06-25 | Extraction separation for Nepal irid isoflavone from kudzu, process for preparing sulfonated compounds thereof , and their pharmaceutical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1594307A true CN1594307A (en) | 2005-03-16 |
Family
ID=34663880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410026271 Pending CN1594307A (en) | 2004-06-25 | 2004-06-25 | Extraction separation for Nepal irid isoflavone from kudzu, process for preparing sulfonated compounds thereof , and their pharmaceutical uses |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1594307A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415732C (en) * | 2005-08-12 | 2008-09-03 | 东北师范大学 | Extraction method and application of kudzu flower isoflavones and monomer irisin and irisin |
| CN100462361C (en) * | 2007-01-31 | 2009-02-18 | 陕西师范大学 | Formononetin-3'-sodium sulfonate, puraphyllin-3'-sodium sulfonate, preparation method and medicinal use thereof |
| CN100471500C (en) * | 2005-07-04 | 2009-03-25 | 山东省医学科学院药物研究所 | Medicinal composition contg. glucoside of pueravia flower and its application |
| CN101239092B (en) * | 2008-03-14 | 2010-10-20 | 山东省医学科学院药物研究所 | Kudzuvine flower isoflavonoid extraction, its extracting method, medicinal composition and its use in pharmaceutical |
| CN101632656B (en) * | 2009-08-04 | 2010-11-03 | 山东省医学科学院药物研究所 | Preparation method of water-soluble irisolidone |
| CN1911924B (en) * | 2006-08-18 | 2011-06-01 | 山东省医学科学院药物研究所 | Extraction method of Nepal eagle tail isoflavone, its derivative and medicipal composition using said derivative as active component |
| CN105153148A (en) * | 2015-06-18 | 2015-12-16 | 玉林师范学院 | Tryptanthrin alkaloid salt, and preparation method and application thereof |
| CN107417653A (en) * | 2017-08-22 | 2017-12-01 | 四川省中医药科学院 | Sulfonate of 6 hydroxy dye lignin 5 ' and its production and use |
-
2004
- 2004-06-25 CN CN 200410026271 patent/CN1594307A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100471500C (en) * | 2005-07-04 | 2009-03-25 | 山东省医学科学院药物研究所 | Medicinal composition contg. glucoside of pueravia flower and its application |
| CN100415732C (en) * | 2005-08-12 | 2008-09-03 | 东北师范大学 | Extraction method and application of kudzu flower isoflavones and monomer irisin and irisin |
| CN1911924B (en) * | 2006-08-18 | 2011-06-01 | 山东省医学科学院药物研究所 | Extraction method of Nepal eagle tail isoflavone, its derivative and medicipal composition using said derivative as active component |
| CN100462361C (en) * | 2007-01-31 | 2009-02-18 | 陕西师范大学 | Formononetin-3'-sodium sulfonate, puraphyllin-3'-sodium sulfonate, preparation method and medicinal use thereof |
| CN101239092B (en) * | 2008-03-14 | 2010-10-20 | 山东省医学科学院药物研究所 | Kudzuvine flower isoflavonoid extraction, its extracting method, medicinal composition and its use in pharmaceutical |
| CN101632656B (en) * | 2009-08-04 | 2010-11-03 | 山东省医学科学院药物研究所 | Preparation method of water-soluble irisolidone |
| CN105153148A (en) * | 2015-06-18 | 2015-12-16 | 玉林师范学院 | Tryptanthrin alkaloid salt, and preparation method and application thereof |
| CN107417653A (en) * | 2017-08-22 | 2017-12-01 | 四川省中医药科学院 | Sulfonate of 6 hydroxy dye lignin 5 ' and its production and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1793132A (en) | Derivative of cyclo membranousol kind and application thereof | |
| JP2016515547A (en) | Triazine compounds with anti-chicken coccidiosis | |
| CN1594307A (en) | Extraction separation for Nepal irid isoflavone from kudzu, process for preparing sulfonated compounds thereof , and their pharmaceutical uses | |
| CN101157692A (en) | Berberine derivatives, preparation methods, pharmaceutical compositions and uses thereof | |
| CN1948332A (en) | Glycyrrhetinic acid-30-acylamide derivatives and its use | |
| JP2014141524A (en) | Five crystal forms of nicousamide compound and preparation method, pharmaceutical composition and usage thereof | |
| CN1245972C (en) | Naringin and its salt used for preparing cough suppressing phlegm tramsforming medicine | |
| CN1033451C (en) | Alpha-substituted benzenemethanamine derivatives | |
| WO2021196949A1 (en) | Crystalline form a of glp-1 receptor agonist and preparation method therefor | |
| CN1219757C (en) | Sulfonated dehydroabietate and its preparing process and application | |
| CN1275958C (en) | Genistein-3'-sodium sulfonate, dimethylation daidzein-3'-sodium sulfonate, their preparing process and pharmaceutical use | |
| CN1872852A (en) | Berberine derivative, preparation method thereof, pharmaceutical composition thereof and application thereof | |
| CN1186051C (en) | 'Huajuhong' preparation and its preparing process | |
| CN1416881A (en) | Medicine composition for treating depression and its prepn | |
| CN1186336C (en) | Prepn and application in preparing medicine of fraxinus general coumarin | |
| CN100462361C (en) | Formononetin-3'-sodium sulfonate, puraphyllin-3'-sodium sulfonate, preparation method and medicinal use thereof | |
| CN100341495C (en) | Solid dispersion and preoral combination of glibenclamide and preparation method | |
| CN1199964C (en) | Soya aglycone-3'-sodium sulfonate and its preparing method and medicinal use | |
| CN106349099A (en) | Caffeic acid-lysine and derivatives, preparation method and application thereof | |
| CN1636997A (en) | Substituted tricyclocoumarin compound and its prepn and anti-HIV application | |
| CN1189177C (en) | Use of chitin oligosaccharide sulphate and/or chitin sulfate for preparing medicine for diabetes | |
| CN1569777A (en) | Chiral source and pharmaceutical salt or complex of organic alkali drug | |
| CN1282473C (en) | Wild chrysanthemum granules and preparation method | |
| CN1118473C (en) | Aqueous soluble steroid compound alkaloid salt, preparation process and medicinal composition containing same | |
| CN1319971C (en) | Camptothecine derivatives and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |